What a baseline panel actually checks

A baseline panel is not one test. It is a group of markers chosen because each one sits somewhere in the path of a metabolic protocol, and any of them can change what gets prescribed.

Thyroid function, because an underactive thyroid produces many of the same complaints as a metabolic problem and is treated completely differently. Kidney and liver markers, because they affect how a drug is cleared. Blood glucose and HbA1c, which describe how your body is handling sugar over months rather than minutes. Iron studies and B12, because deficiency in either produces fatigue that no weight-loss drug will fix.

Why the first draw matters more than the second

Reference ranges describe a population, not a person. They are deliberately wide, and a result sitting near the bottom of a range can be entirely normal for one patient and clearly wrong for another.

Your own earlier value is a far better comparator than a population range, and the baseline draw is the only thing that creates it. This is why we ask for prior labs when patients have them, and why the first review is scheduled around a second draw rather than a calendar date.

Without a first draw, every later result is a number without a direction.

What gets found, and what changes because of it

Most panels come back unremarkable and the protocol proceeds as planned. That is the expected outcome and it is not a wasted test — it is the record that makes every later result readable.

When something does turn up, it is usually ordinary and fixable: low B12, low iron, a thyroid marker drifting. Occasionally it is a reason to treat something else first, or to choose a different therapy. Either way it is better known before you start than discovered three months in.

If a provider does not ask for labs

Some services prescribe on a questionnaire alone. That is faster, and it removes the only objective information anyone has about you.

It is a reasonable question to put to any provider: what will you measure, when will you measure it again, and what result would make you change the plan? A provider who cannot answer that is not monitoring you, only supplying you.

The three usual sites

Subcutaneous means into the fat layer sitting between skin and muscle. Three regions carry enough of it reliably: the abdomen, avoiding a couple of inches around the navel; the outer thigh, roughly the front-outer third; and the back of the upper arm, which most people need help reaching.

None of the three is clinically superior for a weekly injection. Absorption differences between sites exist but are small at weekly dosing intervals. Pick the ones you can reach comfortably and reliably, because the site you can actually use is better than the site you are supposed to prefer.

Rotation is the part people skip

Injecting into the same small area week after week produces lipohypertrophy — a firm, thickened patch of tissue. It is usually painless, easy to miss, and it absorbs unpredictably.

That is where inconsistent weeks come from. A dose that seemed to work and then seemed not to is often a site problem wearing a dose problem's clothes. Move at least an inch from the last spot, and cycle between regions rather than staying loyal to one. Keeping a note of where you went last week makes it automatic.

A dose behaving inconsistently is sometimes a site problem, not a dose problem.

Technique, briefly

Clean the skin and let it dry. Pinching a fold helps in leaner areas and is unnecessary where there is plenty of subcutaneous tissue. Insert at the angle your provider specified for your device and deliver steadily rather than fast.

Cold medication stings more than medication at room temperature. Taking it out of the fridge ten or fifteen minutes ahead removes most of what patients report about the injection itself. Dispose of every needle in a sharps container — never household waste.

What is normal afterwards, and what is not

A small bleb, mild redness or a bruise at the site is ordinary and settles within a day or two. Slight tenderness is common in the first weeks and usually fades as you get used to the process.

Spreading redness, warmth, swelling that worsens rather than improves, or fever are not ordinary and warrant contacting your provider promptly. So does a firm lump that persists between injections — that is the tissue change rotation exists to prevent.

Why the first dose is not meant to work

Every GLP-1 protocol begins at a dose too low to do much. That is deliberate. The starting dose tests whether you tolerate the drug class at all, and it lets the gastrointestinal effects settle before anything is asked of them.

Patients who judge the medication by their first few weeks are judging the wrong thing. Very little about weeks one to four predicts the outcome except whether you were able to keep taking it.

What a schedule is and is not

A standard escalation steps up at fixed intervals, commonly monthly. That interval is a default, not a mandate, and treating it as a mandate is the most common titration error we see.

If nausea is limiting the quality of your food, or side effects are interfering with your week, holding a dose for an extra cycle is not a setback. It is the protocol working as designed. The schedule serves the patient, not the other way round.

The goal is the lowest dose that still produces change. Not the highest dose you can tolerate.

What we watch between steps

Three things decide whether a dose increases: appetite signal, side-effect load, and rate of loss. When appetite suppression is holding and weight is moving at a reasonable pace, there is no clinical reason to escalate.

Dose increases are for stalls, not for calendars. Escalating a dose that is already working trades a better side-effect profile for nothing, and it removes headroom you may want later.

Where most people land

Most patients settle below the maximum labelled dose and stay there. That is the intended outcome, not an underperformance. Titration is the process of finding your number, and it is finished when your number stops changing.

There is also a floor to this. A dose that produces no appetite change and no movement after a fair trial is not the right dose, and staying on it out of caution wastes months. Underdosing and overdosing are both errors; the schedule exists to find the space between them.

What the first two weeks actually are

Your body stores carbohydrate as glycogen, in muscle and liver, and every gram of glycogen is stored with several grams of water. Enter a deficit and that reservoir draws down quickly.

The result is a fast early drop that is real weight and is not fat. It is also not permanent in the way fat loss is: eat a high-carbohydrate meal and some of it returns overnight, which is why the scale can jump two or three pounds for reasons that have nothing to do with the protocol.

Why it looks like the drug stopped working

Once the glycogen reservoir stabilises, the scale slows to the rate at which fat tissue is actually being lost. That rate is much slower and much less dramatic.

Patients experience this as the medication losing effect in month two. It has not. The first phase was measuring one thing and the second phase is measuring another, and only the second one is the outcome anybody was after.

The fast part was never the therapy working. The slow part is.

What a real rate looks like

Fat loss is a slow process measured in weeks, and a sustainable rate is unremarkable to watch. Faster is not better: rapid loss costs a worse proportion of lean mass, which is the outcome you will feel later even if the scale looks better now.

This is why expectations are set against a weekly rate rather than a first-month total, and why the first review is scheduled after the water has finished moving. A first-month number is measuring hydration as much as progress.

How to read the scale without being misled

Weigh under the same conditions each time — same time of day, similar hydration, ideally the same day of the week — and read the weekly average rather than any single morning.

Salt, carbohydrate intake, training load, sleep and the menstrual cycle all move water by several pounds in either direction. A daily weight with a weekly average gives that noise somewhere to go instead of letting it masquerade as progress or failure.

What weight actually measures day to day

Body weight moves with salt intake, carbohydrate intake, training load, sleep quality, bowel timing and the menstrual cycle. Any one of those can swing the number by several pounds in either direction.

Against that background, a fortnight of genuine fat loss can be completely invisible. The scale is not lying, it is simply measuring several things at once and reporting one number for all of them.

Telling a plateau from noise

A true plateau is a rate that has stayed flat across a span long enough for the noise to cancel, measured the same way each time. Most of what patients report as a plateau is shorter than that window.

Weighing daily and reading the weekly average beats weighing once a week, because it gives the variation somewhere to go. Before changing anything, we make sure we are looking at a trend and not at a Tuesday.

Before we change a dose, we make sure we are looking at a trend and not at Tuesday.

The common causes, in the order we check them

Intake drift is first and most common. Portions expand gradually as appetite suppression becomes familiar, and almost nobody notices it happening. A few days of honest recording usually settles the question.

Then protein, which people under-eat on appetite suppression; then sleep, which affects appetite hormones directly; then activity, which quietly falls as weight comes off. Each of those is cheaper and safer to correct than a dose increase.

When a dose change is the answer

Sometimes it genuinely is. A confirmed stall on a dose that once worked, with intake and protein verified and side effects tolerable, is a reasonable case for escalation.

Occasionally the better move is a change of molecule rather than a higher dose of the same one, because the two available mechanisms are not identical. That is a review conversation, made on response rather than preference.

Why protein is the first thing to go

Appetite suppression is indiscriminate. It reduces how much you want to eat without any regard for what your body most needs from the reduced amount.

Protein is dense, filling and slow, which makes it the least attractive option when capacity is limited. Carbohydrate and fat are easier to eat in small volumes, so intake quietly shifts away from the one macronutrient that protects lean tissue.

Why a floor, and why in grams

We set the target in grams rather than as a percentage of intake, because a percentage of a shrinking intake is itself a shrinking number. As total food falls, a percentage target silently reduces the thing it was supposed to protect.

A fixed gram floor does not move when your appetite does. Your provider sets the specific figure at review, based on body composition and what the protocol is trying to preserve.

Set a floor, and hit it before anything else on the plate.

Hitting it when you are not hungry

Front-load. Protein at the first meal is far easier to reach than protein at the last one, after appetite has been suppressed all day. Most people who miss their floor miss it in the evening.

Eat the protein portion first, before anything else on the plate. Liquid sources are useful when solid food is unappealing, because they bypass much of the volume problem. And plan the day's protein rather than hoping the day supplies it.

What it is protecting

Any sustained deficit costs some lean mass. The question is proportion, and protein intake is one of the three things that decide it, alongside rate of loss and resistance training.

Lean tissue is metabolically active, so losing more of it than necessary makes the maintenance phase harder and makes regain easier. Protein is the cheapest of the three inputs to get right, and the one most often neglected.

What the scale cannot tell you

Weight is a single number covering fat, muscle, water, glycogen and gut contents. Two people can lose the same amount and end up in very different physical condition.

That is a limitation of the instrument, not a reason to ignore it. It is the reason we ask about training and protein at review rather than reading progress off the scale alone.

Rate: the input we control with the dose

Faster loss reliably produces a worse ratio of fat to lean tissue. A larger deficit gives the body less reason to preserve metabolically expensive muscle.

Lower-dose protocols trade speed for a better composition, which is why they suit patients whose goal is a body rather than a number. Aggressive dosing is not a shortcut to the same destination; it is a different destination.

The scale cannot tell you what you lost. That is a limitation of the instrument.

Protein: the input patients most often miss

Appetite suppression is indiscriminate, so protein falls unless it is deliberately protected. This is covered in its own chapter, but it belongs in any honest account of lean-mass loss.

Set a floor in grams, front-load it, and eat it first. It is the cheapest of the three inputs and the one most commonly neglected.

Resistance training: the signal that decides what stays

Resistance training tells the body which tissue is still being used and therefore worth keeping. Without that signal, muscle is simply expensive tissue during a shortage.

It does not need to be elaborate. Two or three sessions a week covering the major movement patterns is enough to change the outcome materially. Walking and general activity are valuable for other reasons but do not send the same signal.

How you would actually know

Strength is the most practical proxy most people have. If the weights you handle are holding steady or improving while weight comes off, the composition is probably going the right way.

Body composition measurement is more direct where it is available, but consistency of method matters more than the method chosen. Comparing two different measurement types tells you about the instruments, not about you.

What patients are describing

Ask someone a month into GLP-1 therapy what changed and they rarely lead with weight. They describe a quiet — the running commentary about the next meal simply stopping.

The term food noise gained currency because patients kept reaching for the same metaphor independently. It has no lab value and no billing code, which is part of why it went undocumented for so long.

What is happening mechanically

GLP-1 is a hormone your body already produces after eating, and part of its job is signalling satiety. These medications extend that signal rather than blocking hunger outright.

The distinction matters. Suppression implies overriding a drive by force. Regulation means the signal that should have said enough now arrives and persists, so the decision to stop eating no longer requires effort.

Willpower was never the missing input. The signal was.

Why it predicts whether treatment works

Patients who experience the quiet tend to stay on protocol. Patients who do not are often under-dosed, and that is a fixable problem rather than a reason to conclude the treatment failed.

This is why we ask about it in those words at every review. It moves before the scale does, which makes it an earlier and more useful signal than weight for judging whether a dose is doing its job.

What it does not fix

Quieting the noise removes a constant negotiation. It does not by itself build the habits that make the result durable, and it does not address eating driven by stress, boredom or routine rather than appetite.

Patients who use the quiet period to establish protein intake, training and sleep tend to hold their result. Patients who treat it as the whole intervention tend to find the noise returns with the same habits waiting underneath.

Why it happens

These medications deliberately slow the rate at which the stomach empties. Food stays longer, satiety signals persist, and appetite settles. The same slowing continues further down the digestive tract.

Meanwhile total intake drops. Less food means less fibre and less fluid arriving, at exactly the point the bowel needs both more than usual. The mechanism producing the benefit and the mechanism producing the complaint are the same mechanism.

What actually helps

Fibre first, deliberately rather than incidentally. On reduced intake it has to be planned, because it will not arrive by accident from a smaller plate.

Fluid alongside it, because fibre without adequate water can make matters worse rather than better. Then daily movement — walking is enough; the bowel responds to physical activity more than most people expect. Most cases settle on those three before anything is prescribed for them.

This is the most common complaint we treat, and the one patients are most reluctant to raise.

Raise it early

This is among the most common complaints we treat and the one patients are most reluctant to mention. It gets endured for weeks and then becomes the reason someone quits an otherwise working protocol.

It is an expected effect with an ordinary fix. Raising it in week two is a short conversation; raising it in month three, after it has shaped your eating and your dosing decisions, is a longer one.

When it is not just constipation

Severe or persistent abdominal pain, vomiting that will not settle, inability to pass gas, abdominal swelling, or constipation that does not respond to the ordinary measures are not part of the expected picture.

Those warrant contacting your provider promptly rather than waiting for the next review. The routine version of this is uncomfortable and manageable; the version that is not routine needs assessing rather than enduring.

Why the same drink hits harder

These medications slow how fast the stomach empties. Alcohol reaching the small intestine more slowly and less predictably changes the shape of the curve, not just its height.

Patients routinely describe two glasses behaving like four, and describe it as arriving later and unevenly. The tolerance you remember was calibrated on a stomach that emptied faster. It is worth re-learning your limit deliberately rather than discovering it socially.

What it costs the rest of the protocol

Alcohol fragments sleep even when it shortens the time taken to fall asleep. Fragmented sleep blunts the overnight growth hormone pulse that recovery depends on and raises the following day's appetite.

So a drinking evening tends to undo work being done elsewhere in the protocol — not dramatically, but reliably. That is usually a more relevant consideration than the calories, which patients tend to overweight by comparison.

The tolerance you remember was calibrated on a stomach that emptied faster.

Nausea, and the practical version

Alcohol is irritating to a stomach already emptying slowly, so it can worsen the gastrointestinal effects that titration is trying to settle. That interaction is most noticeable in the days after a dose increase.

The practical version: eat first, go slower than you used to, keep water alongside, and be cautious in the week following any increase. Learn your new limit somewhere it does not matter.

Something patients report unprompted

A number of patients describe wanting alcohol noticeably less on these medications, often without having set out to drink less. It is a recognised and actively researched observation rather than a claimed benefit.

We mention it because patients raise it and are sometimes surprised by it. It is not a reason to start treatment, and it is not something we would predict for any individual.

What short sleep does to the things we treat

Sleep restriction raises evening cortisol, reduces insulin sensitivity, increases the hormone signalling that drives hunger and reduces the one that signals fullness. It also flattens the overnight growth hormone pulse that tissue repair relies on.

Every one of those is something a protocol might otherwise address with a prescription. Treating them pharmacologically while the underlying sleep deficit continues is expensive and, at best, partially effective.

Why we ask before we escalate

When a protocol underperforms, sleep is among the first things we look at, ahead of dose. Not out of austerity — because it is frequently the actual answer and it is cheaper and safer than the alternative.

This is why sleep questions appear early in intake and return at every review. A dose increase layered on top of five hours a night is treating the symptom of a problem nobody has named.

We are not being austere. We are being honest about the order of operations.

When the medication is the thing disturbing sleep

Some patients report disrupted sleep in the first weeks or after a dose increase, often tied to gastrointestinal discomfort rather than to any direct stimulant effect. Eating earlier and lighter in the evening frequently resolves it.

There is also a genuine overlap between metabolic health and sleep-disordered breathing, which is worth raising if you snore heavily, wake unrefreshed, or have been told you stop breathing at night. That is a diagnosis to pursue, not a side effect to tolerate.

What we actually ask people to change

Consistency of timing does more than duration alone. A regular wake time anchors the system even when bedtime varies, and it is the single easiest thing most people can fix.

Then the ordinary levers: light in the morning, less alcohol in the evening, and a last meal early enough that digestion is not competing with sleep. None of this is novel, and none of it is a reason to delay treatment — therapy works better on a foundation already in place, and the foundation costs less than the therapy.

Why temperature matters at all

These are protein molecules, not simple chemicals. Their function depends on holding a specific three-dimensional shape, and heat, light and repeated temperature cycling degrade that structure.

A degraded dose is a weaker dose. It presents exactly like a plateau — same injection, same schedule, less effect — which is why a good share of what reaches us as the medication stopped working turns out to be a storage question.

The rules that actually apply

Refrigerated is the default for unopened product. Do not freeze: freezing damages these molecules and a frozen pen or vial should not be used even after thawing.

Every product carries a defined out-of-fridge window once in use, and it is shorter than most people assume. That window is specific to your product, so read the label you were given rather than generalising from something you read about a different one. Keep it out of direct light.

A pen left in a hot car for an afternoon is not the same pen afterwards.

Travelling with it

Hand luggage, always. Hold temperatures are not controlled and the bag may not arrive when you do. Use a cool pack rather than direct ice contact, since freezing is as damaging as overheating.

Keep the pharmacy label on the packaging — it identifies the medication as prescribed to you, which makes airport screening straightforward. Carry needles in their original packaging, and check requirements at your destination before you fly.

When you are not sure

A pen left in a hot car for an afternoon is not the same pen afterwards. Neither is one that spent a day on a windowsill or was accidentally frozen.

If a dose has been outside its range and you are unsure, ask before using it. Replacing one pen costs considerably less than a wasted month of treatment and a review spent investigating a plateau that was never a plateau.

Why regain is predicted, not a personal failure

Appetite regulation is an effect of the medication, not a permanent change to your physiology. Once the drug clears, the hormonal environment that made the deficit sustainable returns, usually within weeks.

It returns into a body that is now smaller and therefore needs less energy than it did before. Rebound is not a failure of discipline. It is the predicted result of removing the input, and describing it any other way sets patients up to blame themselves for pharmacology.

What maintenance actually is

Maintenance is a protocol in its own right, and it is the part most programmes leave out entirely. Our approach steps the dose down rather than off, and pairs it with energy, sleep and recovery support so the habits built during loss remain possible to keep.

Most patients maintain on a fraction of their loss-phase dose. Some taper off entirely over a longer horizon. Both are planned outcomes, and both are reviewed rather than assumed.

Rebound is not a failure of discipline. It is the predicted result of removing the input.

The question of how long

There is no fixed duration, and any provider offering one without knowing you is guessing. Obesity is managed like other chronic conditions, which for many people means ongoing rather than time-limited treatment.

That is worth knowing before you start rather than discovering at goal weight. The honest framing is that you are choosing a management approach, not completing a course.

What makes a taper more likely to hold

The habits built during the loss phase decide most of it. Patients who used the quieter period to establish protein intake, resistance training and consistent sleep have infrastructure to fall back on; patients who did not are returning to the conditions that produced the original problem.

Stepping down gradually with monitoring beats stopping and hoping. If weight begins moving in the wrong direction, that is information for the next review, not a verdict.

A secretagogue, not a replacement

Sermorelin prompts the pituitary to release growth hormone rather than supplying hormone from outside. That distinction is the practical argument for a secretagogue: the release stays inside your body's own feedback controls.

Exogenous hormone overrides those controls. A secretagogue works within them, which limits how far the signal can be pushed and is a large part of why it is used this way.

Why the timing is not arbitrary

Growth hormone is released in pulses rather than continuously, and the largest natural pulse occurs during the first hours of deep sleep.

Dosing before bed places the signal alongside that pulse instead of against it. This is why patients are asked to inject at night rather than at whatever hour is convenient — the timing is doing part of the work.

If your sleep is broken, sermorelin has less to amplify. We usually fix sleep first.

Why sleep quality comes first

If your sleep is broken, there is less pulse to amplify. A secretagogue timed to a pulse that barely happens is a poor use of a therapy.

So we usually address sleep before or alongside starting, not afterwards. It is a recurring pattern across the formulary: the foundation costs less than the therapy and decides how well the therapy performs.

What to expect, and over what horizon

What patients notice first varies between individuals and is not predictable in advance. Your provider reviews how you are responding at each check-in. Recovery and body composition follow over months rather than weeks, and only when training and protein intake support them.

Sermorelin is a long-horizon therapy. Patients looking for a rapid, visible result are generally better served elsewhere on the formulary, and it is more honest to say so at the start than at month three.

What NAD+ actually does

NAD+ is a coenzyme present in every cell. It carries electrons through the reactions that convert what you eat into usable energy, and it is consumed by repair enzymes that maintain DNA.

Every cell holds a limited pool of it. That pool is not a fuel tank you top up for a burst of performance; it is closer to working capital, and running short lowers the ceiling on what a cell can do before it needs to recover.

Why the pool falls

Levels decline with age, and faster under metabolic stress — poor sleep, alcohol, chronic inflammation, a sustained calorie deficit.

That is worth noticing, because a depleted pool is usually a symptom of something else that is also worth fixing. Treating the marker while the cause continues is a familiar and expensive mistake.

Patients rarely describe NAD+ as energizing. They describe the afternoon as no longer being a problem.

What patients actually report

The result is not fatigue relief in the way caffeine addresses fatigue. Patients rarely describe NAD+ as energising. They describe the afternoon no longer being a problem.

Because it is replenishment rather than stimulation, the timeline is different. Individual response varies and is not predictable in advance. The cellular biology is well established; what an individual patient notices is not.

Being honest about the evidence

NAD+ is a genuinely active area of research and also a heavily marketed one, and those two facts are frequently confused. The cellular biology is well established; the clinical claims made in consumer marketing often run well ahead of it.

We dose it weekly and review it alongside sleep, training load and B12 status, because those are the things most likely to be producing the same complaint. If one of them is the answer, it is a cheaper and more durable answer.

What a reference range is actually telling you

A reference range is built from a sample population, usually as the band containing the middle of that group. It is a statistical description, not a statement about what is optimal for an individual.

That makes the ranges wide by design. A result sitting near an edge can be entirely normal for one patient and clearly abnormal for another with a different history, and the range alone cannot distinguish the two.

Direction beats position

A value that has moved meaningfully within its range across two draws tells us more than a single result sitting near a boundary. Movement is signal; position is context.

This is why we ask for prior labs when patients have them, and why the baseline draw matters more than it appears to at the time. One draw is a data point. Two draws are information.

One draw is a data point. Two draws are information.

Panels explain each other

Markers are not independent. Thyroid function, metabolic markers, iron status and B12 all interact, and treating any one in isolation reliably produces a second problem.

Fatigue is the clearest example: it can come from thyroid, iron, B12 or glucose handling, and the panel read as a whole usually distinguishes them where any single marker cannot.

What changes because of a result

Where a result changes the protocol, your provider should say so plainly and tell you what the next draw is meant to answer. A number that changes nothing and answers nothing did not need drawing.

It is reasonable to ask, of any result: what does this mean, does it change the plan, and when do we look again? Those three questions cover most of what a lab report is for.

What methylation is, briefly

Methylation is a set of reactions that attach a small chemical group to other molecules. It sounds abstract, and it underpins building neurotransmitters, maintaining the myelin around nerves, regulating gene expression and recycling homocysteine.

B12 and folate are central to it. When either runs short, the consequences are diffuse rather than specific, which is exactly why the problem gets missed.

Why it goes undiagnosed

Partly because serum B12 is a poor test. It measures what is circulating, not what has reached cells and been used, so a result within range does not reliably exclude a functional deficiency.

Partly because the symptoms are unglamorous: fatigue, low mood, brain fog, cold hands, pins and needles. Each is easy to attribute to stress, age or a busy period, and the diagnosis often arrives only after other things were ruled out.

It is worth ruling out before you treat anything more interesting.

Absorption is the usual failure point

Most people are not short on intake. They are short on absorption, which depends on stomach acid and intrinsic factor and declines for several ordinary reasons.

Age reduces it. So do metformin, long-term reflux medication and low stomach acid generally. This is why we dose intramuscularly rather than orally when the history suggests malabsorption — an oral dose that is not absorbed is not a dose.

Why it is worth ruling out first

It is inexpensive, it is safe at the doses used, and when it is the answer patients usually know within about two weeks. That combination makes it a sensible thing to exclude before anything more interesting is considered.

It also sits alongside the other common causes of the same complaint — thyroid, iron, sleep — which is why it is read as part of a panel rather than alone.

What approval actually covers

FDA approval covers a specific formulation manufactured to a fixed standard, together with the evidence package behind its labelling. It is a statement about a product, not about a molecule in general.

Compounding does not carry that approval. A compounded preparation is made by a pharmacy for an individual patient, and while the pharmacy is licensed and regulated, the preparation itself has not been through product approval. Anyone telling you otherwise is not being straight with you.

Why compounding exists at all

Compounding is a long-established part of pharmacy practice, intended for situations where an approved product does not meet an individual patient's clinical needs — a required strength that is not commercially available, or an ingredient a patient cannot tolerate.

It is patient-specific by design. That is the framework it operates within, and it is a narrower one than consumer marketing in this category often implies.

The honest comparison is about access and oversight, not about one being quietly better.

The regulatory position keeps moving

This area has changed significantly and is still changing. What was permissible during a national shortage is not necessarily permissible after that shortage is resolved, and the rules governing which substances may be compounded have been actively revisited.

We are not going to summarise the current position in an article that will age. Ask your provider directly what they supply, under what authority, and from which pharmacy — and expect a specific answer rather than reassurance.

What to ask any provider

Which pharmacy is preparing it, and is it licensed in your state. What testing the preparation undergoes. Whether you are receiving a compounded or an approved product, stated plainly and in writing.

Who the prescribing clinician is and how to reach them. What happens if you have an adverse reaction. A provider who answers those readily is doing the job; one who deflects to marketing language is telling you something too.

What an incretin is

Incretins are hormones your gut releases after eating. They prompt insulin release in response to food and contribute to the signalling that tells your brain you have eaten enough.

GLP-1 is the better known of the two. GIP is the other, and it has its own effects on insulin secretion and on how fat tissue handles energy — related to GLP-1's, but not identical.

One receptor or two

Semaglutide targets the GLP-1 receptor. Tirzepatide targets GLP-1 and GIP together, which is why it is described as a dual agonist.

In trials the dual mechanism produces greater average weight loss at broadly comparable tolerability. Averages describe populations, though, and the more useful clinical fact is that individual responses differ in ways the average conceals.

Mechanism is a reason to switch, not only a reason to escalate.

Why this is a reason to switch, not only to escalate

Patients who responded poorly to one sometimes respond well to the other. That is not what you would expect if the second were merely a stronger version of the first.

So when a patient stalls at a maximum tolerated dose, moving pathways is often more productive than pushing the same pathway harder. Mechanism is a reason to switch, not only a reason to escalate.

What is the same

Both are weekly subcutaneous injections with similar titration logic: start low, escalate on response and tolerability, settle at the lowest dose that still produces change.

The side-effect profiles overlap substantially, and gastrointestinal effects dominate both. Nothing about the second receptor removes the need for careful titration.

How the choice actually gets made

At review, on response — not at intake, on preference. Starting history, tolerability, what you have already tried and what is available all feed into it.

A patient doing well on either has no clinical reason to switch. The distinction earns its keep when something is not working, which is precisely when knowing that two mechanisms exist is worth something.